Comparing the efficacy of concurrent capecitabine with external beam radiotherapy versus radiotherapy alone in pain management of osseous metastasis from breast cancer

Sarker M. Tanvir; Nayma Jahan; Suman Paul; Nahid Naznin Rinky; A. T. M. Shazzaeatur Rahaman; Mohammad Saiful Islam Pathan; Mukti Rani Datta; Jannatul Ferdous; Jaynul Abedin

doi:10.18203/2320-6012.ijrms20252379

Authors

Sarker M. Tanvir Department of Radiotherapy, Rangpur Medical College Hospital, Rangpur, Bangladesh
Nayma Jahan Department of Physiology, Rangpur Community Dental College, Rangpur, Bangladesh
Suman Paul Department of Clinical Oncology, Ahsania Mission Cancer and General Hospital, Dhaka, Bangladesh
Nahid Naznin Rinky Department of Radiotherapy, Dhaka Medical College Hospital, Dhaka, Bangladesh
A. T. M. Shazzaeatur Rahaman Dhaka Medical College and Hospital, Dhaka, Bangladesh
Mohammad Saiful Islam Pathan Department of Radiotherapy, Mymensingh Medical College Hospital, Mymensingh, Bangladesh
Mukti Rani Datta Department of Radiotherapy, Dhaka Medical College and Hospital, Dhaka, Bangladesh
Jannatul Ferdous National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
Jaynul Abedin Department of Oncology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20252379

Keywords:

Capecitabine, Radiotherapy, Breast cancer

Abstract

Background: Breast cancer is the most common cancer in women globally, and bone metastases significantly affect the quality of life and survival. This study aimed to compare the efficacy of concurrent capecitabine with EBRT versus EBRT alone in managing pain from osseous metastases in breast cancer patients.

Methods: A quasi-experimental study was conducted with 56 breast cancer patients with bone metastases. Patients were divided into two groups: Group A received EBRT alone, while group B received concurrent capecitabine (825 mg/m², 5 days/week) with EBRT.

Results: In this study, group A (n=28) and group B (n=28) were compared across various parameters. The mean ages were similar (Group A: 42.9±8.4 years, group B: 42.1±12.5 years, p=0.780). ECOG performance status was significantly better in group B (e.g., 12^th week: group A: 1.14±0.65, group B: 0.71±0.59, p=0.012). Treatment response showed that by the 12^th week, 42.9% of group B had a complete response (CR) compared to 14.3% in group A (p=0.027). No significant differences were observed in treatment-related side effects.

Conclusions: The study found that combining capecitabine with EBRT improved pain management and reduced the need for pain medications in breast cancer patients with bone metastasis. Both treatment groups showed similar side effects, indicating good tolerance for both regimens.

Metrics

Metrics Loading ...

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660

Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271-7. DOI: https://doi.org/10.1200/JCO.2009.25.9820

Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19(1):1-12. DOI: https://doi.org/10.1186/s12885-019-6311-z

Tahara RK, Brewer TM, Theriault RL, Ueno NT. Bone metastasis of breast cancer. Adv Exp Med Biol. 2019;1152:105-29. DOI: https://doi.org/10.1007/978-3-030-20301-6_7

Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, et al. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metast. 2015;32:125-33. DOI: https://doi.org/10.1007/s10585-015-9697-2

Khan L, Uy C, Nguyen J, Chow E, Zhang L, Zeng L, et al. Self-reported rates of sleep disturbance in patients with symptomatic bone metastases attending an outpatient radiotherapy clinic. J Palliat Med. 2011;14(6):708-14. DOI: https://doi.org/10.1089/jpm.2010.0491

Zhang H, Zhu W, Biskup E, Yang W, Yang Z, Wang H, et al. Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real-world data. J Bone Oncol. 2018;11:38-50. DOI: https://doi.org/10.1016/j.jbo.2018.01.004

Aliev MD, Stepanova AM, Musaev ER, Valiev AK, Gutorov SL. Metastatic lesion of the spine in patients with breast cancer. prognostic factors. Siberian J Oncol. 2015;(3):61-7.

Litak J, Czyżewski W, Szymoniuk M, Sakwa L, Pasierb B, Litak J, et al. Biological and clinical aspects of metastatic spinal tumors. Cancers. 2022;14(19):4599. DOI: https://doi.org/10.3390/cancers14194599

Zamora R, Davidson DJ, Chansky HA. Manual of Clinical Oncology, 8th edition, Philadelphia: Wolters Kluwer. 2017.

Kimura T. Multidisciplinary approach for bone metastasis: a review. Cancers. 2018;10(6):156. DOI: https://doi.org/10.3390/cancers10060156

Hoveidaei A, Karimi M, Khalafi V, Fazeli P, Hoveidaei AH. Impacts of radiation therapy on quality of life and pain relief in patients with bone metastases. World J Orthoped. 2024;15(9):841. DOI: https://doi.org/10.5312/wjo.v15.i9.841

Migliorini F, Eschweiler J, Trivellas A, Driessen A, Knobe M, Tingart M, et al. Better pain control with 8-gray single fraction palliative radiotherapy for skeletal metastases: a Bayesian network meta-analysis. Clin Exp Metast. 2021;38:197-208. DOI: https://doi.org/10.1007/s10585-020-10067-7

Rich SE, Chow R, Raman S, Zeng KL, Lutz S, Lam H, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radioth Oncol. 2018;126(3):547-57. DOI: https://doi.org/10.1016/j.radonc.2018.01.003

Nguyen J, Cramarossa G, Bruner D, Chen E, Khan L, Leung A, et al. A literature review of symptom clusters in patients with breast cancer. Expert Rev Pharmacoec Outcomes Res. 2011;11(5):533-9. DOI: https://doi.org/10.1586/erp.11.55

Yee C, Wang K, Asthana R, Drost L, Lam H, Lee J, et al. Radiation-induced skin toxicity in breast cancer patients: a systematic review of randomized trials. Clin Breast Can. 2018;18(5):e825-40. DOI: https://doi.org/10.1016/j.clbc.2018.06.015

Ahmed S, Kamal SM, Salah T, Sedik MF, Youssief AA. Concurrent capecitabine with external beam radiotherapy versus radiotherapy alone in painful bone metastasis of breast cancer origin. J Bone Oncol. 2021;31:100395. DOI: https://doi.org/10.1016/j.jbo.2021.100395

Zhu JW, Charkhchi P, Adekunte S, Akbari MR. What is known about breast cancer in young women? Cancers. 2023;15(6):1917. DOI: https://doi.org/10.3390/cancers15061917

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: https://doi.org/10.3322/caac.21492

Kundel Y, Nasser NJ, Purim O, Yerushalmi R, Fenig E, Pfeffer RM, et al. Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin. PLOS One. 2013;8(7):e68327. DOI: https://doi.org/10.1371/journal.pone.0068327